Product Information
RIVASTIGMINE 1.5 MG CAPSULE is a generic product labeled by Aurobindo Pharma Limited, priced at $0.1643 per EA under NDC 65862064860. Its NADAC has been published 485 times since Jun 21, 2017.
FDA first approved this application on Mar 25, 2016. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
1.5 mg/1
Manufacturer
Aurobindo Pharma LimitedNDC
65862064860
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
RIVASTIGMINE TARTRATEApproval Type
Generic (ANDA)
FDA Application
ANDA204572FDA Approved
3/25/2016
TE Code
AB
On Market Since
3/25/2016
Pharmacological Classes
Price Statistics
The NADAC for RIVASTIGMINE 1.5 MG CAPSULE has been published 485 times since Jun 21, 2017, and over the history we have for it it has declined 83.9%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1643 per EA |
|---|---|
| All-time high | $1.0173 (Jul 12, 2017) |
| All-time low | $0.1380 (Nov 22, 2023) |
| 52-week high | $0.1864 |
| 52-week low | $0.1458 |
| Median price | $0.2616 |
| Average price | $0.3164 |
| Largest weekly change | +49.6% (Oct 19, 2022) |
| Weeks tracked | 485 |
| Tracking since | Jun 21, 2017 |
Generic Alternatives
The matcher finds 7 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 8% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Aurobindo Pharma Limited manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Rivastigmine Tartrate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Cholinesterase Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of RIVASTIGMINE 1.5 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for RIVASTIGMINE 1.5 MG CAPSULE, manufactured by Aurobindo Pharma Limited, is $0.1643 per EA (NDC 65862064860), effective Sep 30, 2026.
How has the price of RIVASTIGMINE 1.5 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for RIVASTIGMINE 1.5 MG CAPSULE has declined 83.9%. It has been tracked across 485 weekly CMS publications since Jun 21, 2017.
What are the highest and lowest recorded NADAC prices for RIVASTIGMINE 1.5 MG CAPSULE?
Since Jun 21, 2017, the NADAC for RIVASTIGMINE 1.5 MG CAPSULE has ranged from a low of $0.1380 (Nov 22, 2023) to a high of $1.0173 (Jul 12, 2017), with a median of $0.2616 per EA.
Are there cheaper alternatives to RIVASTIGMINE 1.5 MG CAPSULE?
Yes. 7 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, RIVASTIGMINE 1.5 MG CAPSULE, is $0.1508 per EA — about 8% below RIVASTIGMINE 1.5 MG CAPSULE.
Who manufactures RIVASTIGMINE 1.5 MG CAPSULE?
RIVASTIGMINE 1.5 MG CAPSULE (NDC 65862064860) is labeled by Aurobindo Pharma Limited, and CMS classifies it as a generic product.